collaboration-kings-college-london

Boehringer Ingelheim and King ’s College London join forces to progress new therapeutic concepts in major depressive disorder and schizophreniaThe collaboration will produce a comprehensive clinical research program in major depressive disorder and schizophrenia, building upon Boehringer Ingelheim ’s circuitry-based approach to precision psychiatry and further solidifies commitment to provide better treatments for people living with serious mental health conditions.Together, Boehringer Ingelheim and King ’s College London aim to identify more patient-specific biomarkers, improving the development of therapies for cognitive impairment.
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news